The decision brought an end to an unusually fierce campaign — fought in private and public — by Paris-based rival PAI Partners, which refused to accept it had lost and tried to upend the transaction, ...

After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its ...

The decision brought an end to an unusually fierce campaign — fought in private and public — by Paris-based rival PAI ...

Advent International, Blackstone Inc., Groupe Bruxelles Lambert NV and PAI Partners have also proceeded into the next round ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...

Earlier this month, Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...

With this fundraise, the company is seeking to shore up domestic shareholding with “well-known and credible” names ...

Plus, James Gorman gets a promotion at Disney and how Jeff Yass turned gambling wins into a colossal trading giant ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global ...

CD&R is nearing a deal to acquire control of Sanofi’s consumer health unit after it signed social commitments with the French ...